Ivabradine shows promise in patients with heart failure with diverse risk profiles

An analysis of the SHIFT trial data indicates that ivabradine, a medication used to reduce heart rate, is effective in improving clinical outcomes for patients with heart failure (HF) across various risk indicators.

The study showed that ivabradine produced similar risk reductions in the primary endpoint (cardiovascular death or HF hospitalization) for patients with different risk profiles, including low systolic blood pressure, high resting heart rate, low left ventricular ejection fraction, and high New York Heart Association class.

The reduction in heart rate had a more pronounced effect in patients with higher resting heart rates. Of note, the treatment with ivabradine did not raise any safety concerns.

These findings suggest that early and patient-oriented management of HF with ivabradine could be beneficial for a wide range of HF patients with different risk profiles.

Reference
Abdin A, Komajda M, Borer JS, et al; SHIFT Investigators. Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial). ESC Heart Fail. 2023;doi: 10.1002/ehf2.14455. Epub ahead of print. PMID: 37427483.